📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. The Nonclinical Overview — an integrated, interpretive appraisal of the animal pharmacology, PK, and toxicology.
Why it exists. Unlike the factual Module 2.6 summaries, the Overview argues: it weighs the nonclinical evidence, explains the safety margins, and justifies why human trials are reasonable. It is written by an expert to be read as a scientific opinion.
How it is produced here. No real animal studies were run for this portfolio, so this is deep-knowledge mock: the study designs, endpoints, and conclusions are realistic domain content standing in for real laboratory data.
Format & governing standard. ICH M4S(R2) · M3(R2) · S1–S8
| Field | Value |
|---|---|
| Document ID | M24 |
| Version | 3.0 (full, aligned to M4) |
| Compound | GLPI-103 (GLP-1/APJ dual agonist) |
| Standard | ICH M4S(R2) · M3(R2) · S1–S8 |
| Confidentiality | Confidential |
[MOCK — deep-knowledge assumption]No nonclinical wet-lab data are generated; guideline-structured, scientifically coherent narrative with illustrative values. Detailed study reports in M4 (4.2.1–4.2.3); tabulated summaries in M2.6.
No comments yet. Be the first to say something!
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | Nonclinical | Initial |
| 2.0 | 2026-06-29 | Nonclinical | Full — exposure margins, translational assessment |
| 3.0 | 2026-06-30 | Nonclinical | Aligned to detailed M4 — explicit potency/PK values, specific NOAEL margins, C-cell human-relevance & issue management |
Designed per ICH M3(R2) (study timing relative to clinical phases) and the ICH S-series, using the rat (rodent) and cynomolgus monkey (non-rodent) to characterise dual pharmacology, ADME, and toxicology adequate for Phase 1–3 and registration. Peptide-specific considerations (immunogenicity, IV local tolerance, the SNAC permeation enhancer) were included.
No off-target hits (~80-target screen); hERG IC₅₀ >30 µM (>1,000× margin); no QTc prolongation; no adverse CNS/respiratory effects; only a transient, monitorable, mechanism-related heart-rate increase (+10–15%).
Low clearance and a long half-life driven by >99% albumin binding (C18-diacid acylation) plus DPP-4 resistance (Aib substitutions) — supporting once-weekly IV dosing; single-digit-% oral bioavailability with the SNAC enhancer (basis for the 8 mg oral vs 4 mg IV dose). Metabolism is proteolytic (non-CYP) with low drug-interaction potential; ADA were low-titre and non-neutralising.
| Study | NOAEL | Margin to clinical AUC |
|---|---|---|
| Repeat-dose rat (26 wk) | high dose (3.0 mg/kg/wk) | ≈25× |
| Repeat-dose monkey (39 wk) | high dose | ≈20× |
| Reproductive (rat/rabbit) | maternal-toxicity-limited | adequate developmental margin |
| Margins support the proposed clinical doses (IV 4 mg QW; Oral 8 mg QD). |
The nonclinical findings translate to monitorable clinical risks carried as adverse events of special interest (gastrointestinal tolerability, thyroid C-cell/MTC, pancreatitis, cardiovascular/heart-rate) (PROT-301 §10; RMP). The package establishes the dual GLP-1/APJ mechanism, a class-consistent and manageable safety profile, and adequate exposure margins — supporting clinical development and registration, with the single notable finding (rodent C-cell carcinogenicity) investigated and managed as a labeled, low-human-relevance class risk.